Weichao Chen

TL;DR: A series of phenyl pyrazole inverse agonists optimized for selectivity, aqueous solubility, antiplatelet activity, low hERG activity, and good pharmacokinetic properties are described, resulting in the discovery of 10k (APD791), a potential treatment for arterial thrombosis.

TL;DR: The discovery and optimization of (7-benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acids as potent, centrally available, direct acting S1P1 functional antagonists, with favorable pharmacokinetic and safety properties are described.

TL;DR: In this article, amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH), idiopathic PAH, familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH

TL;DR: The presente invention concerne les agonistes du recepteur GPR119 : 3-fluoro-4-(5-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl),pyrimidin -4-ylamino)- N, N -dimethylbenzamide, ainsi que leurs sels, solvates et hydrates de qualite pharmaceutique, utiles en tant qu'agent pharmace